Trial · NCT07891234
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
NCT07891234, Phase 4, Not yet recruiting, Sherihan AboElyazed Mohamed Khalil
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance. Trials, record NCT07891234. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891234
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
- NCT number
- NCT07891234
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 66 participants, estimated
- Lead sponsor
- Sherihan AboElyazed Mohamed Khalil
- Conditions
- MAFLD in Prediabetes and Diabetes
- Interventions
- Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab)
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Liver fibrosis | one year | Liver fibrosis will be evaluated using vibration-controlled transient elastography (VCTE) with controlled attenuation parameter (CAP) technology. We will measure liver stiffness (LSM) in kilopascals (kPa) using a FibroScan 502 Touch device equipped with both M and XL probes. We will assess these parameter on day 0, then reassess after 3 months and 1 year. |
| Primary | Liver steatosis | one year | Liver steatosis will be evaluated using vibration-controlled transient elastography (VCTE) with controlled attenuation parameter (CAP) technology, using a FibroScan 502 Touch device equipped with both M and XL probes. CAP in decibels per meter (dB/m). We will assess these parameter on day 0, then reassess after 3 months and 1 year. |
| Primary | Fibrosis (FIB-4) score | one year | FIB-4 score = (Age x AST) / (Platelets x √(ALT)) Will be assessed on day 0, then reassessed after 3 months and 1 year. |
| Primary | NAFLD fibrosis score | one year | NAFLD fibrosis score = -1.675 + (0.037 x age \[years\]) + (0.094 x BMI \[kg/m²\]) + (1.13 x IFG/diabetes \[yes = 1, no = 0\]) + (0.99 x AST/ALT ratio) - (0.013 x platelet count \[×109/L\]) - (0.66 x albumin \[g/dl\]). Will be assessed on day 0, then reassessed after 3 months and 1 year. |
| Secondary | Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) | one year | HOMA-IR: \[fasting insulin (microU/L) x fasting glucose (mg/dL) / 405\]. Will be assessed on day 0, then reassessed after 3 months and 1 year |
| Secondary | Glycated hemoglobin (HbA1C) | one year | Glycated hemoglobin (HbA1c) will be measured on day 0, then followed up after 3 months and 1 year |
| Secondary | blood pressure control | one year | Measurements of systolic and diastolic blood pressure (mmHg). Will be measured on day 0, then reassessed after 3 months and 1 year. |
| Secondary | lipid profile | one year | Lipid profile (total cholesterol, LDL, triglycerides, HDL, and non-HDL). Will be assessed on day 0, then reassessed after 3 months and 1 year. |
| Secondary | Body mass index (BMI) | one year | BMI = weight in kilograms/height in square meters. Will be assessed on day 0, then reassessed after 3 months and 1 year. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891234
GET https://conductscience.org/api/trials/v1/NCT07891234/registered